SCHEMBL34464751

SCHEMBL34464751

CCNNC(=O)c1ccc(-c2ccnc(Nc3ccc(C(=O)N4CCOCC4)cc3)n2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 18/20 0.61
▸ JAK3 P52333 14/20 0.61
▸ JAK1 P23458 6/20 0.61
▸ TYK2 P29597 2/20 0.61
▸ HDAC1 Q13547 2/20 0.61
▸ HDAC3 O15379 1/20 0.61
▸ NCOR1 O75376 1/20 0.61
▸ HDAC2 Q92769 1/20 0.61
▸ HDAC8 Q9BY41 1/20 0.61
▸ HDAC6 Q9UBN7 1/20 0.61
▸ PLK4 O00444 2/20 0.59
▸ BMPR1B O00238 1/20 0.59
▸ CIT O14578 1/20 0.59
▸ GAK O14976 1/20 0.59
▸ OPA1 O60313 1/20 0.59
▸ ROCK2 O75116 1/20 0.59
▸ STK16 O75716 1/20 0.59
▸ PRKD3 O94806 1/20 0.59
▸ CSNK2A2 P19784 1/20 0.59
▸ CDK2 P24941 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34464776 0.88 JAK2 (0.58) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL14021578 0.86 JAK2 (0.64) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL34464822 0.85 JAK2 (0.50) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL34464779 0.85 JAK2 (0.65) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL34464763 0.84 JAK2 (0.62) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL14021223 0.84 JAK2 (0.64) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL34464805 0.83 JAK2 (0.58) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL16156897 0.80 JAK2 (0.81) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL8312552 0.80 JAK2 (0.60) JAK2JAK3JAK1TYK2HDAC1
SCHEMBL34464814 0.80 JAK2 (0.54) JAK2JAK3JAK1TYK2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE BAERENKRAFT THERAPEUTICS LLC (US) 2026-04-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260109690-A1 HDAC6 INHIBITORS AND METHOD OF THEIR USE HDAC6, HDAC3, HDAC1 JAK2 2639/4885JAK3 3362/4885JAK1 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback